LuciDabra (Dabrafenib) is a revolutionary kinase inhibitor that targets patients with unresectable or metastatic melanoma harboring the BRAF V600E mutation.

LuciDac 15 mg Tablet

Molecule : DacomitinibManufacturer : Lucius Pharma

LuciDac 45 mg Tablet

Molecule : DacomitinibManufacturer : Lucius Pharma

LuciDap 1 mg Tablet

Molecule : DaprodustatManufacturer : Lucius Pharma

LuciDasa 20 mg Tablet

Molecule : DasatinibManufacturer : Lucius Pharma

LuciDasa 50 mg Tablet

Molecule : DasatinibManufacturer : Lucius Pharma

LuciDasa 70 mg Tablet

Molecule : DasatinibManufacturer : Lucius Pharma

LuciDela 150 mg Tablet

Molecule : IdelalisibManufacturer : Lucius Pharma

LuciDeucra 6 mg Tablet

Molecule : DeucravacitinibManufacturer : Lucius Pharma

LuciElace 345 mg Tablet

Molecule : ElacestrantManufacturer : Lucius Pharma

LuciElace 86 mg Tablet

Molecule : ElacestrantManufacturer : Lucius Pharma

LuciElafib 80 mg Tablet

Molecule : ElafibranorManufacturer : Lucius Pharma

LuciElo 25 mg Tablet

Molecule : EltrombopagManufacturer : Lucius Pharma

LuciElo 50 mg Tablet

Molecule : EltrombopagManufacturer : Lucius Pharma

LuciEna 50 mg Tablet

Molecule : EnasidenibManufacturer : Lucius Pharma

LuciEncor 75 mg Capsule

Molecule : EncorafenibManufacturer : Lucius Pharma

Please fill in the details below, and we’ll get back to you as soon as possible